We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Rho GTPases in Gynecologic Cancers: In-Depth Analysis toward the Paradigm Change from Reactive to Predictive, Preventive, and Personalized Medical Approach Benefiting the Patient and Healthcare.
- Authors
Zubor, Pavol; Dankova, Zuzana; Kolkova, Zuzana; Holubekova, Veronika; Brany, Dusan; Mersakova, Sandra; Samec, Marek; Liskova, Alena; Koklesova, Lenka; Kubatka, Peter; Bujnak, Jan; Kajo, Karol; Mlyncek, Milos; Giordano, Frank A.; Golubnitschaja, Olga
- Abstract
Rho guanosine triphospatases (GTPases) resemble a conserved family of GTP-binding proteins regulating actin cytoskeleton dynamics and several signaling pathways central for the cell. Rho GTPases create a so-called Ras-superfamily of GTPases subdivided into subgroups comprising at least 20 members. Rho GTPases play a key regulatory role in gene expression, cell cycle control and proliferation, epithelial cell polarity, cell migration, survival, and apoptosis, among others. They also have tissue-related functions including angiogenesis being involved in inflammatory and wound healing processes. Contextually, any abnormality in the Rho GTPase function may result in severe consequences at molecular, cellular, and tissue levels. Rho GTPases also play a key role in tumorigenesis and metastatic disease. Corresponding mechanisms include a number of targets such as kinases and scaffold/adaptor-like proteins initiating GTPases-related signaling cascades. The accumulated evidence demonstrates the oncogenic relevance of Rho GTPases for several solid malignancies including breast, liver, bladder, melanoma, testicular, lung, central nervous system (CNS), head and neck, cervical, and ovarian cancers. Furthermore, Rho GTPases play a crucial role in the development of radio- and chemoresistance e.g. under cisplatin-based cancer treatment. This article provides an in-depth overview on the role of Rho GTPases in gynecological cancers, highlights relevant signaling pathways and pathomechanisms, and sheds light on their involvement in tumor progression, metastatic spread, and radio/chemo resistance. In addition, insights into a spectrum of novel biomarkers and innovative approaches based on the paradigm shift from reactive to predictive, preventive, and personalized medicine are provided.
- Subjects
CANCER chemotherapy; CARRIER proteins; CELLULAR signal transduction; DRUG resistance in cancer cells; FEMALE reproductive organ tumors; METASTASIS; RADIOTHERAPY; TUMOR markers; PREDICTIVE validity; PATIENT-centered care
- Publication
Cancers, 2020, Vol 12, Issue 5, p1292
- ISSN
2072-6694
- Publication type
Article
- DOI
10.3390/cancers12051292